This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Merck Spent $1.5M In 3Q Lobbying On Health Reform

WASHINGTON (AP) ¿ Drugmaker Merck & Co. Inc. spent nearly $1.6 million in the third quarter lobbying on health care overhaul issues, vaccine funding and government price controls on drugs, according to a recent disclosure form.

The $1.56 million total was up 41 percent from the $1.11 million that the maker of asthma and allergy drug Singulair, diabetes pill Januvia and cholesterol pills Vytorin and Zetia spent lobbying in the year-ago period.

Merck, based in Whitehouse Station, N.J., leapfrogged to become the world's second-biggest drugmaker with its $41 billion purchase of Schering-Plough Corp. in November.

Merck lobbied on multiple health care issues, including supporting additional coverage for uninsured people, having public-private partnerships involved in research comparing the effectiveness of different medical treatments, and providing coverage for preventive services including immunizations.

It specifically supported increased funding for the National Immunization Program for low-income children and access to vaccines for adults under Medicare. Merck, a pioneer in vaccines, sells nearly every shot recommended for both children and adults.

Merck lobbied against allowing cheaper prescription drugs to be imported back into the U.S. from other countries, except by the drug's manufacturer, a hot issue in this year's debate over the health care overhaul; the White House says it still backs such imports. Merck also supported efforts to require that the government certify the safety and cost savings of drugs if reimportation is allowed.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,570.21 +213.34 1.23%
S&P 500 2,033.96 +21.07 1.05%
NASDAQ 4,700.5110 +56.1990 1.21%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs